Jafron Biomedical Co.,Ltd. (SHE:300529)

Market Cap	13.36B -21.7%
Revenue (ttm)	2.02B -18.4%
Net Income	564.55M -22.0%
EPS	0.74 -20.0%
Shares Out	774.36M
PE Ratio	23.34
Forward PE	21.30
Dividend	0.52 (2.93%)
Ex-Dividend Date	Jun 1, 2026

Volume	3,807,390
Open	17.91
Previous Close	17.73
Day's Range	17.19 - 17.91
52-Week Range	17.21 - 24.98
Beta	0.42
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 7, 2026

About Jafron Biomedical

Jafron Biomedical Co.,Ltd. engages in the research, development, production, and sale of blood purification products for hemadsorption field worldwide. The company offers therapies for kidney, liver, and critical diseases, as well as poisoning. It also provides HA series disposable hemoperfusion cartridge; BS series disposable plasma bilirubin perfusion adsorption column; blood purification machine; and other products, such as JM hemodialyzer, DNA230, disinfectant, hemodialysis concentrate, resin bandage, online hemodialysis B powder bag/bucket...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 1989
• Employees: 2,301
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 300529

Financial Performance

In 2025, Jafron Biomedical's revenue was 2.01 billion, a decrease of -24.86% compared to the previous year's 2.68 billion. Earnings were 532.82 million, a decrease of -35.04%.